<DOC>
	<DOCNO>NCT02461264</DOCNO>
	<brief_summary>Patients acute hematological disease ( acute leukemia , aplastic anemia , hematopoietic stem cell autologous allogeneic ... ) hospitalize intensive care unit hematology require compensation anemia thrombocytopenia blood transfusion red blood pack cell ( RBP ) platelet concentrate ( PC ) .The AFSSAPS ( Agence Française de Sécurité Sanitaire des Produits de Santé ) recommendation ( 2002 ) specify need transfuse 2 RBP case symptomatic anemia usually hemoglobin 6 10 g / dL . These recommendation allow transfuse single RBP elderly patient case associated heart disease ( heart failure ) . A recent development ( 2012 ) post-transfusion pulmonary edema overload recommend transfusion unit unit high risk patient . More recently , Swiss team historically compare transfusion policy 2 139 patient hematological malignancy . The first group receive 2 RBP transfusion case symptomatic anemia hemoglobin level &lt; 6 g / dL . The group receive 1 RBP transfusion . In total 2212 unit 1548 transfusion perform 1 RBP transfusion policy result 25 % decrease number RBP use without complication . In prospective single-center pilot study , show transfuse single RBP possible without increase side effect anemia , without complication allow overall reduction consumption red blood cell unit . Several meta-analyzes report intensive care bleed situation restrictive use transfusion significantly reduce cardiac event , bleeding , bacterial infection mortality . The number patient treat prevent one death 33 . The main objective demonstrate randomize trial restrictive strategy ( transfusion single unit transfusion ) inferior liberal strategy ( transfusion 2 unit transfusion ) term severe complication . Transfusion perform case hemoglobin level &lt; 8g/dL . Key secondary objective reduce number RBP use cost hospitalization comparison complications/mortality 2 group .</brief_summary>
	<brief_title>Transfusion Strategy Hematological Intensive Care Unit</brief_title>
	<detailed_description />
	<criteria>Inpatients either acute leukemia patient receive intensive chemotherapy autologous transplantation lymphoma , allogeneic stem cell transplantation ischemic heart failure acute promyelocytic leukemia ALKERAN autologous conditioning ( myeloma patient ) disseminate intravascular coagulation hemorrhagic syndrome stroke vital distress diagnosis creatinine clearance &lt; 50 ml/min liver disease ALT ( alanine aminotransferase ) /AST ( aspartate aminotransferase ) ≥2.5 ULN ( upper limit normal ) ( except relate tumor ) pregnant female autoimmune hemolytic anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>